https://www.nature.com/articles/d41586-021-03552-w Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * My Account Login * Explore content * About the journal * Publish with us Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 25 November 2021 Heavily mutated coronavirus variant puts scientists on alert Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines' effectiveness. * Ewen Callaway 1. Ewen Callaway View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email You have full access to this article via your institution. Download PDF People wearing personal protective equipment pick up a suspected COVID-19 patient Medics at an infectious-disease unit in South Africa, where a new strain of COVID is spreading quickly.Credit: Alet Pretorius/Gallo Images/Getty Researchers in South Africa are racing to track the concerning rise of a new variant of the coronavirus that causes COVID-19. The variant harbours a large number of mutations found in other variants, including Delta, and it seems to be spreading quickly across South Africa. A top priority is to track the variant more closely as it spreads: it was first identified in Botswana this month and has turned up in travellers to Hong Kong from South Africa. Scientists are also trying to understand the variant's properties, such as whether it can evade immune responses triggered by vaccines and whether it causes more or less severe disease than other variants do. "We're flying at warp speed," says Penny Moore, a virologist at the University of Witwatersrand in Johannesburg, whose lab is gauging the variant's potential to dodge immunity from vaccines and previous infections. There are anecdotal reports of reinfections and cases in vaccinated individuals, but "at this stage it's too early to tell anything," Moore adds. "There's a lot we don't understand about this variant," Richard Lessells, an infectious disease physician at the University of KwaZulu-Natal in Durban, South Africa, said at a press briefing organized by South Africa's health department on 25 November. "The mutation profile gives us concern, but now we need to do the work to understand the significance of this variant and what it means for the response to the pandemic." A World Health Organization (WHO) expert group will meet on 26 November, and will likely label the strain -- currently known as B.1.1.529 -- as a variant of concern or variant of interest, Tulio de Oliveira, a bioinformatician at the University of KwaZulu-Natal, said at the briefing. The variant would likely be named Nu -- the next available letter in the Greek naming system for coronavirus variants -- if it is flagged by the WHO group. Researchers also want to measure the variant's potential to spread globally, possibly sparking new waves of infection or exacerbating ongoing rises being driven by Delta. Changes to spike Researchers spotted B.1.1.529 in genome-sequencing data from Botswana. The variant stood out because it contains more than 30 changes to the spike protein -- the SARS-CoV-2 protein that recognizes host cells and is the main target of the body's immune responses. Many of the changes have been found in variants such as Delta and Alpha and are linked to heightened infectivity and the ability to evade infection-blocking antibodies. But the variant's apparent sharp rise in South Africa's Gauteng province -- home to Johannesburg -- is also setting off alarm bells. Cases increased rapidly in the province in November, particularly in schools and among young people, according to Lessells. Genome sequencing and other genetic analysis from de Oliveria's team found that the B.1.1.529 variant was responsible for all of 77 of the virus samples they analysed from Gauteng, collected between 12 and 20 November. Analysis of hundreds more samples are in the works. The variant harbours a spike mutation that allows it to be detected by genotyping tests that deliver results much more rapidly than genome sequencing, Lessells said. Preliminary evidence from these tests suggest that B.1.1.529 is spreading much wider than Gauteng. "It gives us concern that this variant may already be circulating quite widely in the country," Lessells said. Vaccine effectiveness To understand the threat B.1.1.529 poses, researchers will be closely tracking its spread in South Africa and beyond. Researchers in South Africa mobilized efforts to quickly study the Beta variant, identified there in late 2020, and a similar effort is starting to study B.1.1.529. Moore's team -- which provided some of the first data on Beta's ability to dodge immunity -- has begun work on B.1.1.529. They plan to test the virus's ability to evade infection-blocking antibodies, as well as other immune responses. The variant harbours a high number of mutations in regions of the spike protein that antibodies recognize, potentially dampening their potency. "Many mutations we know are problematic, but many more look like they are likely contributing to further evasion," says Moore. There are even hints from computer modelling that B.1.1.529 could dodge immunity conferred by another component of the immune system called T cells, says Moore. Her team hopes to have its first results in two weeks. "A burning question is does it reduce vaccine effectiveness, because it has so many changes," says Aris Katzourakis, who studies virus evolution at the University of Oxford, UK. Researchers in South Africa will also study whether B.1.1.529 causes disease that is more severe or milder than other variants produce, Lessells said. "The really key question comes around disease severity." So far, the threat B.1.1.529 poses beyond South Africa is far from clear, researchers say. It is unclear whether the variant is more transmissible than Delta, says Moore, because there are currently low numbers of COVID-19 cases in South Africa. "We're in a lull," she says. Katzourakis says that countries where Delta is highly prevalent should be watching for signs of B.1.1.529. "We need to see what this virus does in terms of competitive success and whether it will increase in prevalence." doi: https://doi.org/10.1038/d41586-021-03552-w Subjects * Virology * SARS-CoV-2 Latest on: Virology Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation Article 25 NOV 21 The N501Y spike substitution enhances SARS-CoV-2 infection and transmission Article 24 NOV 21 Do vaccines protect against long COVID? What the data say Do vaccines protect against long COVID? What the data say News Feature 23 NOV 21 SARS-CoV-2 Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation Article 25 NOV 21 The N501Y spike substitution enhances SARS-CoV-2 infection and transmission Article 24 NOV 21 Do vaccines protect against long COVID? What the data say Do vaccines protect against long COVID? What the data say News Feature 23 NOV 21 Nature Careers Jobs * Associate/Senior Editor, Nature Microbiology Springer Nature London, United Kingdom * Computational Biologist (f/m/x) Heinrich Heine University Dusseldorf (HHU) Dusseldorf, North Rhine-Westphalia, Germany * CHAIR and ASSOCIATE PROFESSOR/PROFESSOR Department of Molecular Genetics University of Toronto University of Toronto (U of T) Toronto, Canada * Clinical Project Manager European Vaccine Initiative (EVI) Heidelberg, Baden-Wurttemberg, Germany You have full access to this article via your institution. Download PDF Subjects * Virology * SARS-CoV-2 Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Awards * Journal Impact * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap Nature portfolio * About us * Press releases * Press office * Contact us * * * Discover content * Journals A-Z * Articles by subject * Nano * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Nature Research Academies Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Career development * Nature Careers * Nature Conferences * Nature events Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East Legal & Privacy * Privacy Policy * Use of cookies * Manage cookies/Do not sell my data * Legal notice * Accessibility statement * Terms & Conditions * California Privacy Statement Springer Nature (c) 2021 Springer Nature Limited